OTLC
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $0 | -$342,243 |
| 2025 Q4 | 0.59 | $0 | -$783,020 |
| 2025 Q3 | -0.00 | $0 | -$307,027 |
| 2025 Q2 | 0.00 | $0 | -$126,151 |
| 2025 Q1 | -0.00 | $0 | -$166,955 |
| 2024 Q4 | -0.00 | $0 | -$103,880 |
| 2024 Q3 | -0.01 | $0 | -$143,198 |
| 2024 Q2 | -0.00 | $0 | -$231,416 |